Bartlett & Co Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Bartlett & Co Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$160	Buy	+11	New	+$195	﹤0.01%	1289

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bartlett & Co Wealth Management's SMMT Position: Q2 2026 in Review

Bartlett & Co Wealth Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 11 shares worth $160. The stake represents ﹤0.01% of the portfolio and ranks #1289 among its holdings.

242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Bartlett & Co Wealth Management held 11 shares of Summit Therapeutics worth $160 as of Q2 2026.
Summit Therapeutics was a new Bartlett & Co Wealth Management position in Q2 2026.
Summit Therapeutics made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q2 2026, its #1289 holding.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.